Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Dermata Therapeutics (Nasdaq: DRMA) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held at the Lotte New York Palace Hotel, with virtual participation options available. Gerry Proehl, Chairman, President, and CEO of Dermata, will present an overview of the company's business and provide an update on their Phase 3 acne program.
The conference will feature over 550 company presentations, available both live and on-demand. Investors interested in attending Dermata's presentation can register through the provided link. The company's virtual presentation will be available on-demand starting September 9 at 7:00 A.M. Eastern Time.
Dermata Therapeutics (Nasdaq: DRMA) ha annunciato la sua partecipazione alla 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright, in programma dal 9 all'11 settembre 2024. L'evento si terrà presso il Lotte New York Palace Hotel, con opzioni di partecipazione virtuale disponibili. Gerry Proehl, Presidente e CEO di Dermata, presenterà una panoramica del business dell'azienda e fornirà un aggiornamento sul loro programma di acne di Fase 3.
La conferenza includerà oltre 550 presentazioni aziendali, disponibili sia in diretta che on-demand. Gli investitori interessati a partecipare alla presentazione di Dermata possono registrarsi attraverso il link fornito. La presentazione virtuale dell'azienda sarà disponibile on-demand a partire dal 9 settembre alle 7:00 A.M. Eastern Time.
Dermata Therapeutics (Nasdaq: DRMA) ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright, programada para el 9 al 11 de septiembre de 2024. El evento se llevará a cabo en el Lotte New York Palace Hotel, con opciones de participación virtual disponibles. Gerry Proehl, Presidente y CEO de Dermata, presentará una visión general del negocio de la compañía y actualizará sobre su programa de acné de Fase 3.
La conferencia contará con más de 550 presentaciones de empresas, disponibles tanto en vivo como bajo demanda. Los inversores interesados en asistir a la presentación de Dermata pueden registrarse a través del enlace proporcionado. La presentación virtual de la empresa estará disponible bajo demanda a partir del 9 de septiembre a las 7:00 A.M. Hora del Este.
Dermata Therapeutics (Nasdaq: DRMA)는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 진행되며, Lotte New York Palace Hotel에서 개최됩니다. 가상 참여 옵션도 제공됩니다. Gerry Proehl는 Dermata의 회장, 사장이자 CEO로서 회사 비즈니스에 대한 개요를 발표하고 3상 여드름 프로그램에 대한 업데이트를 제공할 것입니다.
이번 컨퍼런스에서는 550개 이상의 기업 발표가 있을 예정이며, 생중계 및 주문형으로 제공됩니다. Dermata의 발표에 참석하고자 하는 투자자는 제공된 링크를 통해 등록할 수 있습니다. 회사의 가상 발표는 9월 9일 오전 7:00 동부 표준시부터 주문형으로 확인할 수 있습니다.
Dermata Therapeutics (Nasdaq: DRMA) a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright, prévue du 9 au 11 septembre 2024. L'événement se tiendra à l'hôtel Lotte New York Palace, avec des options de participation virtuelle disponibles. Gerry Proehl, Président et CEO de Dermata, présentera un aperçu des activités de l'entreprise et fournira une mise à jour sur leur programme anti-acné de Phase 3.
La conférence comprendra plus de 550 présentations d'entreprises, disponibles en direct et à la demande. Les investisseurs souhaitant assister à la présentation de Dermata peuvent s'inscrire via le lien fourni. La présentation virtuelle de l'entreprise sera disponible à la demande à partir du 9 septembre à 7h00, heure de l'Est.
Dermata Therapeutics (Nasdaq: DRMA) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben, die vom 9. bis 11. September 2024 stattfindet. Die Veranstaltung findet im Lotte New York Palace Hotel statt, wobei auch virtuelle Teilnahmeoptionen verfügbar sind. Gerry Proehl, Vorsitzender, Präsident und CEO von Dermata, wird einen Überblick über das Geschäft des Unternehmens geben und ein Update zu ihrem Phase-3-Akne-Programm bereitstellen.
Die Konferenz wird über 550 Unternehmenspräsentationen bieten, die sowohl live als auch on-demand verfügbar sind. Investoren, die an Dermatas Präsentation teilnehmen möchten, können sich über den bereitgestellten Link registrieren. Die virtuelle Präsentation des Unternehmens wird ab dem 9. September um 7:00 Uhr Eastern Time on-demand zur Verfügung stehen.
- Participation in a major investment conference, potentially increasing visibility to investors
- Opportunity to present updates on the company's Phase 3 acne program
- None.
SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024.
The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at
455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, will provide an overview of the Company's business and an update on the Company's Phase 3 acne program during the presentation.
If you are an investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.
Over 550 corporate presentations and panels are available during September 9-11, 2024.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Time: 7:00AM (Eastern Time)
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET)
About Dermata Therapeutics
Dermata Therapeutics, Inc. is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform and is currently being evaluated in a Phase 3 program. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of the Company's product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.
Investors:
Sean Proehl
Associate General Counsel
info@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on accesswire.com
FAQ
When is Dermata Therapeutics (DRMA) presenting at the H.C. Wainwright Global Investment Conference?
What will Dermata Therapeutics (DRMA) discuss in their presentation at the H.C. Wainwright conference?
Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?
How can investors access Dermata Therapeutics' (DRMA) presentation at the H.C. Wainwright conference?
